BD Partners with Opentrons to Innovate Lab Automation for Enhanced Biomedical Research
- BD partners with Opentrons to integrate robotic liquid-handling into the BD Rhapsody® HT Xpress System for enhanced cellular studies.
- The collaboration aims to automate workflows, improving efficiency and accuracy in single-cell multiomics experiments for researchers.
- BD will offer early access to new automation capabilities, facilitating scientific discovery in biomedical research and innovation.
BD Expands Its Horizons Through Innovative Partnership with Opentrons Labworks
Becton, Dickinson and Company (BD), a leader in medical technology, forges a multi-year collaboration with Opentrons Labworks, Inc., a key player in accessible lab automation. This partnership centers around integrating robotic liquid-handling capabilities into BD’s single-cell multiomics instruments, significantly enhancing the BD Rhapsody® HT Xpress System, which is tailored for extensive cellular studies. By automating critical experimental processes, BD and Opentrons aim to revolutionize disease research and drug development, particularly in high-impact fields such as oncology and immunology.
The collaboration focuses on streamlining workflows for single-cell multiomics experiments. Ranga Partha, PhD, who serves as the VP/GM of Global Marketing and Strategic Growth Areas at BD Biosciences, emphasizes that this integration will empower scientists to achieve quicker, scalable, and more reproducible insights into cellular biology. The partnership will see the BD Rhapsody™ System integrated with the Opentrons Flex® platform, paving the way for hands-free workflows that enhance efficiency and accuracy in laboratory settings. This integration is set to transform how researchers conduct experiments, enabling them to focus more on analysis and discovery rather than manual processes.
A critical component of this partnership is the development of an automation-compatible module for the BD Rhapsody™ System. This module will automate essential steps such as next-generation sequencing library preparation and cell capture, thereby reducing the burden on researchers and expediting the path from experimentation to results. James Atwood, PhD, CEO of Opentrons Labworks, underscores the complementary strengths of both companies, with BD’s expertise in single-cell multiomics aligning perfectly with Opentrons' flexible automation solutions. The collaboration not only enhances the accessibility of advanced single-cell sequencing but also aims to make it more cost-effective for laboratories engaged in both basic and translational research.
In addition to the technological advancements, BD plans to announce early access opportunities for laboratories interested in leveraging these new capabilities. This initiative is expected to create new pathways for scientific discovery, particularly in understanding complex biological systems and developing novel therapeutic strategies. By integrating cutting-edge automation into their systems, BD is set to play a pivotal role in the future of biomedical research and innovation.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

